0:000:00
<p class="MsoNormal"><span style= "font-size: 12pt; font-family: arial, helvetica, sans-serif;">Dr. John Sweetenham and Dr. James Foran discuss the evolving treatment landscape in acute myeloid leukemia, including new targeted therapies, advances in immunotherapy, and the current role for allogeneic transplantation.</span></p> <p class="MsoNormal"><span style= "font-size: 12pt; font-family: arial, helvetica, sans-serif;"><strong> <u>TRANSCRIPT</u></strong></span></p> <p class="MsoNormal"><span style= "font-size: 12pt; font-family: arial, helvetica, sans-serif;"><strong> Dr. John Sweetenham:</strong> Hello, I'm Dr. John Sweetenham, the host of the <em>ASCO Daily News</em> Podcast. There has been steady progress in the therapies for acute myeloid leukemia (AML) in recent years, largely based on an increasing understanding of the molecular mechanisms which underlie the disease. On today's episode, we'll be discussing the evolving treatment landscape in AML. We'll explore risk group strati...